← 返回

SAMSN1 抑制肝细胞癌中 NK 细胞介导的抗肿瘤免疫

英文原题:SAMSN1 restrains NK cell mediated anti-tumor immunity in hepatocellular carcinoma.

查看英文原题

SAMSN1 restrains NK cell mediated anti-tumor immunity in hepatocellular carcinoma.

PubMed 2026/01/21(内容时间) Nat Commun Q1 · IF 18.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

NK细胞是抗肿瘤免疫的关键介质,其功能在肿瘤微环境中常受到损害。在此,我们确定SAM结构域、SH3结构域和核定位信号1(SAMSN1)为一个此前未被识别的免疫检查点,在肝细胞癌(HCC)中主要调控NK细胞功能。单细胞RNA测序(scRNA-seq)分析显示,HCC患者瘤内NK细胞中SAMSN1显著上调,与颗粒酶B表达降低和预后不良相关。在原位Hepa1-6肝细胞癌模型中,全身性Samsn1敲除(Samsn1 -/-)小鼠表现出34%的肿瘤负荷减少,同时NK细胞颗粒酶B产生增强(P = 0.0002)。关键的是,仅NK细胞特异性缺失(Samsn1 f/f -Ncr1 Cre+)即可重现这一治疗效果(41%的肿瘤负荷减少,P = 0.0017),表明SAMSN1主要通过对瘤内NK细胞而非HCC微环境中其他免疫细胞群发挥作用。在机制上,SAMSN1抑制NK细胞活化、增殖和颗粒酶B产生。这些发现表明SAMSN1是一个可靶向的NK细胞检查点,对HCC免疫治疗具有直接的治疗意义。

展开英文摘要原文

NK cells are critical mediators of anti-tumor immunity whose function is frequently compromised in the tumor microenvironment.

Here we identify SAM domain, SH3 domain and nuclear localization signals 1 (SAMSN1) as a previously unrecognized immune checkpoint that predominantly regulates NK cell function in hepatocellular carcinoma (HCC). Single-cell RNA sequencing (scRNA-seq) analysis reveals significant SAMSN1 upregulation in intratumoral NK cells from HCC patients, correlating with reduced granzyme B expression and poor prognosis.

In orthotopic Hepa1-6 hepatocellular carcinoma models, global Samsn1 knockout (Samsn1 -/- ) mice exhibits 34% tumor burden reduction with enhanced NK cell granzyme B production (P = 0. 0002). Critically, NK cell-specific deletion alone (Samsn1 f/f -Ncr1 Cre+ ) recapitulates this therapeutic effect (41% tumor burden reduction, P = 0. 0017), demonstrating that SAMSN1 functions predominantly through intratumoral NK cells rather than other immune populations in the HCC microenvironment.

Mechanistically, SAMSN1 suppresses NK cell activation, proliferation, and granzyme B production.

These findings indicate SAMSN1 as a targetable NK cell checkpoint with direct therapeutic implications for HCC immunotherapy.

论文信息

作者
Wang R、Chen H、Liu H、Li Q、Yao G、Li F、Sun P、Dai T
第一作者单位
Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of University of Science and Technology of China (USTC), University of Science and Technology of China, Hefei, China.China
通讯作者单位
Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of University of Science and Technology of China (USTC), University of Science and Technology of China, Hefei, China. charless@ustc.edu.cn.China
期刊
Nature communications2026 Jan 21
原文标识
PubMed 41565668 · DOI 10.1038/s41467-026-68661-4